Cadila Healthcare is currently trading at Rs. 233.45, up by 8.80 points or 3.92% from its previous closing of Rs. 224.65 on the BSE.
The scrip opened at Rs. 219.00 and has touched a high and low of Rs. 235.00 and Rs. 219.00 respectively. So far 253177 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 375.00 on 14-Nov-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 238.00 and Rs. 219.00 respectively. The current market cap of the company is Rs. 23899.27 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.
Cadila Healthcare has acquired 15% equity share capital of Zydus Technologies (ZTL), a subsidiary company in which the company is already holding 85% equity share capital. Pursuant to the same, ZTL has become a wholly owned subsidiary company.
Further, the company has also acquired 15% common stock of Zydus Noveltech Inc., USA (ZNI), a subsidiary company in which the company is already holding 35% common stock. In view of the same, both ZTL and ZNI will become wholly owned subsidiary companies of the company.
Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.